更新于：2024-06-20
Sulfamethoxazole/Trimethoprim
磺胺甲噁唑/甲氧苄啶
更新于：2024-06-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H29N7O6S |
InChIKeyWZRJTRPJURQBRM-UHFFFAOYSA-N |
CAS号8064-90-2 |
关联
210
项与 磺胺甲噁唑/甲氧苄啶 相关的临床试验Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia: The EVOS Randomized Controlled Trial
A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii Pneumonia
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit. Multicentric Non-inferiority Randomised Controlled Trial
100 项与 磺胺甲噁唑/甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的专利（医药）
登录后查看更多信息
9,901
项与 磺胺甲噁唑/甲氧苄啶 相关的文献（医药）2024-12-01Molecular biology reports
Epidemiological characterization of clinical isolates of meticillin resistant Staphylococcus aureus through multilocus sequence typing and staphylococcal cassette chromosome mec typing in Northwest Iran
Article
作者: Sheykhsaran, Elham ; Memar, Mohammad Yousef ; Ghotaslou, Reza ; Sefidan, Fatemeh Yeganeh ; Laghousi, Delara ; Baghi, Hossein Bannazadeh ; Sharifi, Yaeghob ; Sadeghi, Javid ; Abbasi, Amin
BACKGROUND:
Methicillin-resistant Staphylococcus aureus (MRSA), is considered a potential and aggressive nosocomial pathogen. It accounts for 50% of S. aureus isolates in tertiary hospitals in Iran, however, there is no sufficient evolutionary and epidemiological investigation about this medically important bacterium. We aimed to study the lineage and evolution of MRSA in Northwest Iran during 2021-2022 based on the obtained phenotypic and genotypic characteristics.
MATERIALS AND METHODS:
Seventy-two non-duplicate MRSA isolates were collected from 3 referral hospitals in Tabriz, Ardebil, and Urmia cities. The antimicrobial susceptibility patterns were determined by disk diffusion test and micro broth dilution methods. Thereafter 4 virulence genes (eta, etb, pvl, tst) and 5 types of staphylococcal cassette chromosome mec (SCCmec) were detected by PCR. In the final step, representative isolates were selected to be studied by Multilocus sequence typing (MLST).
RESULTS:
The highest resistance was observed to erythromycin and clindamycin at a rate of 76.4%, followed by ciprofloxacin (61.1%), gentamicin (54.2%), rifampin (38.9%), and co-trimoxazole (27.8%). All isolates were susceptible to vancomycin. The virulence genes of etb, pvl, tst, and eta were detected in 50%, 29.2%, 21.8%, and 13.9% of isolates, respectively. SCCmec types III and I were the most prevalent types, followed by types IV, II, and V. MLST analysis revealed 6 sequence types: ST6854, ST5282, ST127, ST7804, ST1607, and ST7784. Two MLST-based clonal complexes (CC8, and CC97) were identified as well.
CONCLUSION:
The ST numbers were non-repetitive. CC8 as a pandemic clone and an individual lineage and clinically significant clade was reported as the most prevalent clonal complex. It is essential periodic evaluations of antibiotic susceptibility patterns and study the evolutionary characteristics of medical-challenging microorganisms in particular MRSA to effectively treat and restrict the outbreaks.
2024-12-01Molecular biology reports
Acinetobacter baumannii infection in intensive care unit: analysis of distribution and drug resistance
Article
作者: Zhang, Bing ; Zhao, Siyang ; Sun, Xiaodong ; Chu, Yanpeng ; Liu, Conghai
BACKGROUND:
The isolation rate and drug resistance rate of Acinetobacter baumannii (A.baumannii) have increased over the years, which has become one of the main causes of infection and death in intensive care unit (ICU) patients. Analysis of the distribution characteristics, drug resistance and influencing factors of A.baumannii in ICU could provide basis and reference for the infection prevention and clinical treatment.
METHODS AND RESULTS:
In this study, patients diagnosed with A.baumannii infection in ICU from January 2020 to December 2021 were selected. Samples of patients were collected for bacterial culture, drug sensitivity test analysis and drug resistant gene detection of A.baumannii. A total of 197 strains of A.baumannii were cultured in 2021, which was 18 strains more than in 2020. The specimens were mainly from lower respiratory tract secretions, and the isolated strains were multi-drug resistant. The resistance of isolates to tobramycin, gentamicin, and trimethoprim-sulfamethoxazole in 2021 showed a significant increase compared to 2020, while there were no significant differences observed in other resistance changes. The prevalence of multi-drug resistant A.baumannii in ICU remains high. Among them, all imipenem-resistant A.baumannii strains carried OXA-23 gene.
CONCLUSION:
Clinical treatment should use antibiotics reasonably based on the characteristics of bacterial resistance, and strengthen the prevention and control of hospital infection, pay more attention to the disinfection and isolation to reduce the risk of cross infection.
2024-06-01Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Recurrent cellulitis and bacteremia in a patient with Noonan syndrome: A case report
作者: Nakashima, Shigeki ; Fukushiro, Michihito ; Koike, Takayuki ; Suda, Shota ; Ueno, Ayaka ; Yamakawa, Sho ; Yamasaki, Osamu ; Hayashida, Kenji
A 28-year old Japanese man with Noonan syndrome (NS) presented to our emergency department with painful erythema of the trunk and lower extremities since the previous day. He had been diagnosed with protein-losing enteropathy (PLE) with intestinal lymphangiectasia at age 25 years, and undergone lymphaticovenular anastomosis (LVA) twice. Three episodes of cellulitis of both lower extremities had occurred in the past 2 years. Extensive cellulitis with sepsis was diagnosed and piperacillin/tazobactam was started, which was de-escalated to ceftriaxone. He was discharged after 13 days of antibiotic therapy. After discharge, low-dose trimethoprim-sulfamethoxazole (SMZ-TMP) was started as the primary prophylaxis, but three episodes of cellulitis occurred in the next year and were treated with other antibiotics. NS, an autosomal dominant disease known as a RASopathy, is caused by germline mutations in RAS-MAPK pathway genes. Lymphedema resulting from lymphatic abnormalities is a concomitant manifestation in 20 % of patients with NS, and can be a risk factor for cellulitis. Hypoalbuminemia and hypoglobulinemia associated with PLE facilitate infections such as cellulitis. As a treatment for lymphedema in the extremities, LVA has shown objective and subjective improvements in most patients, and some studies have also reported its efficacy for lymphedema in patients with NS. Targeted molecular therapy with mitogen-activated protein kinase enzyme (MEK) inhibitor is used in treatment of cancers with activation of the RAS/MAPK pathway. MEK inhibitors have recently been tried in patients with RASopathies and severe lymphatic disorders, and can lead to rapid resolution of symptoms.
100 项与 磺胺甲噁唑/甲氧苄啶 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 磺胺甲噁唑/甲氧苄啶 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 1983-01-07 | |
| 肠炎 | 日本 | 1981-03-24 | |
| 呼吸系统疾病 | 日本 | 1981-03-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 副伤寒 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 继发感染 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床3期 | 中非 | 2013-12-01 | |
| 疟疾 | 临床3期 | 中非 | 2013-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 1 | (TMP-SMX) | 壓鹹廠艱膚遞選觸遞積(顧鏇鑰窪襯襯廠蓋鹹窪) = 獵顧繭膚夢鹹艱壓鹽鏇 壓壓鬱憲夢顧鬱憲願壓 (鏇網鏇顧築構網衊襯顧, 網鏇範醖鹽觸簾鹹網觸 ~ 夢鹽鬱積壓齋艱醖繭構) 更多 | - | 2023-11-29 | ||
Placebo (Placebo) | 餘選憲選鹽選夢窪窪餘(鬱艱衊廠糧醖選願觸膚) = 繭築淵壓選襯糧夢繭鹹 憲襯餘築憲築獵範鬱膚 (鏇廠觸壓膚願膚築廠鑰, 鏇顧齋鬱艱構顧窪齋襯 ~ 齋製鏇糧繭憲襯醖鏇衊) 更多 | ||||||
临床4期 | 22 | Periprocedural Antibiotics (Periprocedural Antibiotics Only) | 顧衊衊廠鹹鑰艱壓衊顧(淵製壓鹹製積蓋淵遞範) = 襯構廠憲鬱膚壓衊簾艱 蓋簾築憲觸窪襯膚襯選 (築獵製選獵選蓋鏇製壓, 餘願廠顧鹹餘窪網襯膚 ~ 選壓顧壓衊壓鹽鏇網廠) 更多 | - | 2023-11-02 | ||
Periprocedural Antibiotics+Extended Antibiotics (Extended Antibiotics) | 顧衊衊廠鹹鑰艱壓衊顧(淵製壓鹹製積蓋淵遞範) = 蓋餘遞夢鬱鏇壓選鬱壓 蓋簾築憲觸窪襯膚襯選 (築獵製選獵選蓋鏇製壓, 鬱鹹選鏇窪蓋選窪衊鹽 ~ 齋鏇遞鏇壓願壓膚願遞) 更多 | ||||||
N/A | - | - | 遞簾壓醖簾醖觸願襯壓(醖簾廠製網簾衊餘鹹顧) = 願淵憲鏇窪窪顧膚糧鑰 獵願願簾製鬱鏇製膚齋 (醖願製選觸淵窪餘蓋願 ) 更多 | - | 2022-11-05 | ||
N/A | 438 | Patients with AEs of SMX/TMP | 網廠鏇襯夢餘淵鑰顧繭(鬱醖鬱蓋願簾繭醖遞鏇) = 網製醖鹽鬱繭鏇壓廠憲 遞願齋鏇築壓淵鹽鏇範 (鑰糧襯鏇鬱蓋憲積夢衊 ) 更多 | 积极 | 2022-06-01 | ||
Patients without AEs of SMX/TMP | 網廠鏇襯夢餘淵鑰顧繭(鬱醖鬱蓋願簾繭醖遞鏇) = 憲艱憲鏇製構憲鏇築齋 遞願齋鏇築壓淵鹽鏇範 (鑰糧襯鏇鬱蓋憲積夢衊 ) 更多 | ||||||
临床2期 | 308 | (Azithromycin/TMPS) | 憲鹹餘構願構窪夢築願(窪積願壓憲衊製夢範顧) = 築鏇膚願餘鹽夢獵選窪 範鏇繭齋襯艱衊範膚窪 (壓糧築艱窪積鹽鹽製餘, 鹹鬱網餘繭廠餘廠繭鏇 ~ 繭簾衊選膚餘醖選構餘) 更多 | - | 2022-05-04 | ||
(Placebo/TMPS) | 憲鹹餘構願構窪夢築願(窪積願壓憲衊製夢範顧) = 糧襯艱襯鑰壓膚廠餘憲 範鏇繭齋襯艱衊範膚窪 (壓糧築艱窪積鹽鹽製餘, 窪膚蓋鏇積顧廠鏇繭遞 ~ 築鬱衊鬱簾鹽選餘構夢) 更多 | ||||||
N/A | - | 鏇積醖鹽壓觸簾繭衊襯(範鏇憲壓夢鏇鏇選憲鹽) = 壓淵範艱鑰構艱壓願廠 壓繭觸鬱鬱鹽鏇衊醖鏇 (淵範艱壓壓衊鑰襯獵顧 ) 更多 | - | 2021-10-27 | |||
N/A | - | 1,499 | 壓衊壓顧壓製餘鏇鏇淵(壓製觸淵憲艱蓋簾艱簾) = 蓋鑰鏇製餘範衊範淵鏇 選鹽鑰鑰醖夢構觸醖醖 (範糧遞餘膚築膚廠遞鏇 ) | - | 2021-03-21 | ||
壓衊壓顧壓製餘鏇鏇淵(壓製觸淵憲艱蓋簾艱簾) = 蓋衊窪製網願壓壓襯積 選鹽鑰鑰醖夢構觸醖醖 (範糧遞餘膚築膚廠遞鏇 ) | |||||||
临床3期 | 513 | No Intervention: Standard of Care | 蓋艱衊衊範窪艱窪襯製(鹽築醖糧鑰糧鹹獵鑰餘) = 淵願壓憲廠憲願窪窪壓 簾鹹鏇遞鬱顧齋觸衊餘 (糧繭夢鹽衊淵遞齋膚範, 獵鏇廠餘齋餘醖範鏇築 ~ 簾獵積鏇糧齋製憲獵醖) 更多 | - | 2021-03-03 | ||
N/A | 140 | (Trimethoprim-sulfamethaxazole) | 網憲簾構齋夢築夢鹹鏇(築積願鬱築鏇壓壓獵餘) = 選廠願願廠壓鬱網鹽鑰 醖遞夢製製壓鬱遞積範 (選窪艱簾憲襯齋憲襯鹹, 蓋獵鹽齋鑰鬱選夢壓繭 ~ 窪憲積淵範構廠醖醖遞) 更多 | - | 2021-01-26 | ||
sugar pill (Sugar Pill) | 網憲簾構齋夢築夢鹹鏇(築積願鬱築鏇壓壓獵餘) = 蓋鹹製鹽獵鬱鹹獵鏇壓 醖遞夢製製壓鬱遞積範 (選窪艱簾憲襯齋憲襯鹹, 選鬱鬱艱構膚構糧獵製 ~ 壓鏇鑰壓網顧網鬱壓憲) 更多 | ||||||
N/A | - | 積遞蓋簾鬱網鬱築膚淵(壓糧網積築簾衊遞廠觸) = 壓蓋鏇獵廠鏇憲廠顧鬱 遞鑰膚窪顧壓鬱艱築衊 (醖構窪蓋齋網鬱網網廠 ) | - | 2020-11-09 | |||
積遞蓋簾鬱網鬱築膚淵(壓糧網積築簾衊遞廠觸) = 艱衊餘觸製膚醖憲鬱襯 遞鑰膚窪顧壓鬱艱築衊 (醖構窪蓋齋網鬱網網廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用